In a rat model of experimental retinopathy of prematurity (ROP), the safety of enalaprilat and its effect on the level of angiotensin-converting enzyme (ACE) and angiotensin-II (AT-II) in the vitreous body and retina were investigated. The study was performed on 136 newborn Wistar rat pups divided into 2 groups: group A — experimental (animals with ROP, n=64) and group B — control (n=72). Each group was further divided into 2 subgroups: A0 and B0 (n=32 and n=36, respectively) — animals that did not receive injections of enalaprilat, and A1 and B1 (n=32 and n=36, respectively) — animals treated with daily intraperitoneal (i.p.) injections of enalaprilat (0.6 mg/kg of body weight). This treatment started on day 2 and lasted either to day 7 or to day 14 in accordance with the therapeutic scheme. Animals were taken out of the experiment on day 7 and day 14. In samples of the vitreous body and retina, the content of ACE and AT-II was determined by enzyme immunoassay. On day 7 in subgroups A1 and B1 the levels of ACE and AT-II in the vitreous did not differ, while on day 14 were lower than in subgroups A0 and B0, respectively. Changes in the parameters studied in the retina were somewhat different from those found in the vitreous body. On the seventh day, the level of ACE in the retina of animals of subgroup B1 did not differ significantly from subgroup B0, and in subgroup A1 it was increased compared to subgroup A0. On day 14, its significant decrease was noted in subgroups A1 and B1 as compared with subgroups A0 and B0. At the same time, the level of AT-II in the retina of rat pups of subgroup B1 was lower than in subgroup B0, both on day 7 and day 14. On day 7, the concentration of AT-II, as well as the concentration of ACE, increased in subgroup A1 as compared to subgroup A0. On day 14, this parameter in subgroup A1 was significantly lower as compared to subgroup A0, but significantly higher than in subgroup B1. It should be noted that i.p. injections of enalaprilat, increased a death rate of animals of both groups. The use of enalaprilat, starting from the preclinical period of the ROP development, led to a decrease in the activity of the renin-angiotensin system (RAS) in ROP animals at the onset of retinopathy in the experimental model used. This opens up prospects for considering enalaprilat as a means of preventing the development of this pathology; however, the recognized high toxicity of the drug requires further studies and correction of the timing of its administration and dosage in order to achieve a balance of efficacy and safety of use in order to prevent the development of ROP in children.
Keywords: retinopathy of prematurity, experimental model, prevention, enalaprilat
Katargina L.A., Chesnokova N.B., Pavlenko T.A., Beznos O.V., Osipova N.A., Panova A.Yu. (2023) Enalaprilat as a new means of preventing the development of retinopathy of prematurity. Biomeditsinskaya Khimiya, 69(2), 97-103.
Katargina L.A. et al. Enalaprilat as a new means of preventing the development of retinopathy of prematurity // Biomeditsinskaya Khimiya. - 2023. - V. 69. -N 2. - P. 97-103.
Katargina L.A. et al., "Enalaprilat as a new means of preventing the development of retinopathy of prematurity." Biomeditsinskaya Khimiya 69.2 (2023): 97-103.
Katargina, L. A., Chesnokova, N. B., Pavlenko, T. A., Beznos, O. V., Osipova, N. A., Panova, A. Yu. (2023). Enalaprilat as a new means of preventing the development of retinopathy of prematurity. Biomeditsinskaya Khimiya, 69(2), 97-103.
Hong E.H., Shin Y.U., Cho H. (2022) Retinopathy of prematurity: A review of epidemiology and current treatment strategies. Clin. Exp. Pediatr., 65(3), 115-126. CrossRef Scholar google search
Mikhailova L.А., Katargina L.A. (2021) Resources of Children's Ophthalmological Service in the Russian Federation and their effectiveness. Rossijskaja Pediatricheskaja Oftal'mologija, 16(4), 47-54. CrossRef Scholar google search
Saydasheva E.I., Gorelik Yu.V., Buyanovskaya S.V., Kovshov F.V. (2015) Retinopathy of prematurity: The course and results of treatment in children with gestational age less than 27 weeks. Rossijskaja Pediatricheskaja Oftal'mologija, 10(2), 28-32. CrossRef Scholar google search
Hellgren K.M., Tornqvist K., Jakobsson P.G., Lundgren P., Carlsson B., Källén K., Serenius F., Hellström A., Holmström G. (2016) Ophthalmologic outcome of extremely preterm infants at 6.5 years of age: extremely preterm infants in Sweden study (EXPRESS). JAMA Ophthalmology, 134, 555-562. CrossRef Scholar google search
Molloy C.S., Anderson P.J., Anderson V.A., Doyle L.W. (2016) The long-term outcome of extremely preterm (<28 weeks' gestational age) infants with and without severe retinopathy of prematurity. J. Neuropsychology, 10, 276-294. CrossRef Scholar google search
Glass T.J.A., Chau V., Gardiner J., Foong J., Vinall J., Zwicker J.G., Grunau R.E., Synnes A., Poskitt K.J., Miller S.P. (2017) Severe retinopathy of prematurity predicts delayed white matter maturation and poorer neurodevelopment. Arch. Dis. Child. Fetal Neonatal. Ed., 102, F532-F537. CrossRef Scholar google search
Nath M., Chandra P., Halder N., Singh B., Kumar Deorari A., Kumar A., Azad R., Velpandian T. (2016) Involvement of renin-angiotensin system in retinopathy of prematurity — a possible target for therapeutic intervention. PLoS One, 11(12), e0168809. CrossRef Scholar google search
Tamarat R., Silvestre J.S., Durie M., Levy B.I. (2002) Angiotensin II angiogenic effect in vivo involves vascular endothelial growth factor- and inflammation-related pathways. Laboratory Investigation, 82, 747-756. CrossRef Scholar google search
Asahara T., Chen D., Takahashi T., Fujikawa K., Kearney M., Magner M., Yancopoulos G.D., Isner J.M. (1998) Tie2 receptor ligands, angiopoietin-1 and angiopoietin-2, modulate VEGF-induced postnatal neovascularization. Circ. Res., 83, 233-240. CrossRef Scholar google search
Katargina L.A., Chesnokova N.B., Beznos O.V., Osipova N.A., Panova A.Yu. (2020) Angiotensin-II as a trigger factor in the development of retinopathy of prematurity. Ophthalmologija, 17(4), 746-751. CrossRef Scholar google search
Sharpe D.N., Murphy J., Coxon R., Hannan S.F. (1984) Enalapril in patients with chronic heart failure: A placebo-controlled, randomized, double-blind study. Circulation, 70, 271-278. CrossRef Scholar google search
Abraham P.A., Opsahl J.A., Halstenson C.E., Keane W.F. (1988) Efficacy and renal effects of enalapril therapy for hypertensive patients with chronic renal insufficiency. Arch. Intern. Med., 148, 2358-2362. CrossRef Scholar google search
Faisal M., Cawello W., Laeer S., The LENA Consortium (2021) Clinical pharmacokinetics of enalapril and enalaprilat in pediatric patients — a systematic review. Front. Pediatr., 9, 611322. CrossRef Scholar google search
Katargina L.A., Khoroshilova-Maslova I.P., Majbogin A.M., Panova I.G., Osipova N.A. (2017) Pathomorphological features of the development of experimental retinopathy of prematurity. Mezhdunarodnyj Zhurnal Prikladnyh i Fundamental'nyh Issledovanij, 3(2), 190-194. CrossRef Scholar google search
Lowry O., Rosebrough N., Farr A., Randall R. (1951) Protein mеasurement with the folin phenol reagent. J. Biol. Chem., 193, 265-275. CrossRef Scholar google search
Osipova N.A. (2016) Kliniko-eksperimental'noe izuchenie patogeneza retinopatii nedonoshennyh. Diss. kand. nauk, Helmholtz Institute of Eye Diseases, Moscow. Scholar google search
Sarlos S., Wilkinson-Berka J.L. (2005) The renin-angiotensin system and the developing retinal vasculature. Invest. Ophthalmol. Vis. Sci., 46(3), 1069-1077. CrossRef Scholar google search